Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell. 2002;110:669–72. https://doi.org/10.1016/S0092-8674(02)00966-2.

Article  CAS  PubMed  Google Scholar 

Cohen BD, Kiener PA, Green JM, Foy L, Fell HP, Zhang K. The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells. J Biol Chem. 1996;271:30897–903. https://doi.org/10.1074/jbc.271.48.30897.

Article  CAS  PubMed  Google Scholar 

Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 2011;71:1871–82. https://doi.org/10.1158/0008-5472.CAN-10-1872.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Montemurro F, Scaltriti M. Biomarkers of drugs targeting HER-family signalling in cancer. J Pathol. 2014;232:219–29. https://doi.org/10.1002/path.4269.

Article  CAS  PubMed  Google Scholar 

Bang Y-J, Cutsem EV, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97. https://doi.org/10.1016/S0140-6736(10)61121-X.

Article  CAS  PubMed  Google Scholar 

Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab in HER2-positive gastric cancer. N Engl J Med. 2024;391(14):1360–2. https://doi.org/10.1056/NEJMc2408121.

Article  PubMed  PubMed Central  Google Scholar 

Hecht JR, Bang Y-J, Qin SK, Chung HC, Xu JM, Park JO, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2–positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013/LOGiC—a randomized phase III trial. J Clin Oncol. 2015;34:443–51. https://doi.org/10.1200/JCO.2015.62.6598.

Article  CAS  PubMed  Google Scholar 

Shah MA, Xu R, Bang Y-J, Hoff PM, Liu T, Herráez-Baranda LA, et al. HELOISE: phase IIIb randomized multicenter study comparing standard-of-care and higher-dose trastuzumab regimens combined with chemotherapy as first-line therapy in patients with human epidermal growth factor receptor 2–positive metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol. 2017;35(22):2558–67. https://doi.org/10.1200/JCO.2016.71.6852.

Article  CAS  PubMed  Google Scholar 

Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19:1372–84. https://doi.org/10.1016/S1470-2045(18)30481-9.

Article  CAS  PubMed  Google Scholar 

Satoh T, Xu R-H, Chung HC, Sun G-P, Doi T, Xu J-M, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in asian populations: TyTAN—a randomized phase III study. J Clin Oncol. 2014;32:2039–49. https://doi.org/10.1200/jco.2013.53.6136.

Article  CAS  PubMed  Google Scholar 

Thuss-Patience PC, Shah MA, Ohtsu A, Cutsem EV, Ajani JA, Castro H, et al. Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol. 2017;18:640–53. https://doi.org/10.1016/s1470-2045(17)30111-0.

Article  CAS  PubMed  Google Scholar 

Makiyama A, Sukawa Y, Kashiwada T, Kawada J, Hosokawa A, Horie Y, et al. Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT Study). J Clin Oncol. 2020;38:1919–27. https://doi.org/10.1200/jco.19.03077.

Article  CAS  PubMed  Google Scholar 

Kim CG, Jung M, Kim HS, Lee C, Jeung H-C, Koo D-H, et al. Trastuzumab combined with ramucirumab and paclitaxel in patients with previously treated human epidermal growth factor receptor 2–positive advanced gastric or gastroesophageal junction cancer. J Clin Oncol. 2023;41:4394–405. https://doi.org/10.1200/jco.22.02122.

Article  CAS  PubMed  Google Scholar 

Mishima S, Shitara K. Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer. Expert Opin Biol Ther. 2021;21:825–30. https://doi.org/10.1080/14712598.2021.1912007.

Article  CAS  PubMed  Google Scholar 

Shitara K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, et al. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. New Engl J Med. 2020;382:2419–30. https://doi.org/10.1056/nejmoa2004413.

Article  CAS  PubMed  Google Scholar 

Cutsem EV, di Bartolomeo M, Smyth E, Chau I, Park H, Siena S, et al. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24:744–56. https://doi.org/10.1016/S1470-2045(23)00215-2.

Article  PubMed  PubMed Central  Google Scholar 

Shitara K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, et al. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. Nat Med. 2024;30(7):1933–42. https://doi.org/10.1038/s41591-024-02992-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rivera F, Izquierdo-Manuel M, García-Alfonso P, de Castro EM, Gallego J, Limón ML, et al. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. Eur J Cancer. 2021;145:158–67. https://doi.org/10.1016/j.ejca.2020.12.005.

Article  CAS  PubMed  Google Scholar 

Hofheinz R, Hegewisch-Becker S, Kunzmann V, Thuss-Patience P, Fuchs M, Homann N, et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: a phase II trial of the arbeitsgemeinschaft internistische onkologie gastric cancer study group. Int J Cancer. 2021;149:1322–31. https://doi.org/10.1002/ijc.33696.

Article  CAS  PubMed  Google Scholar 

Hofheinz R-D, Merx K, Haag GM, Springfeld C, Ettrich T, Borchert K, et al. FLOT versus FLOT/Trastuzumab/Pertuzumab perioperative therapy of human epidermal growth factor receptor 2–positive resectable esophagogastric adenocarcinoma: a randomized phase II trial of the AIO EGA study group. J Clin Oncol. 2022;40:3750–61. https://doi.org/10.1200/jco.22.00380.

Article  CAS  PubMed  Google Scholar 

Wagner AD, Grabsch HI, Mauer M, Romario UF, Kang Y-K, Bouche O, et al. Integration of trastuzumab (T), with or without pertuzumab (P), into perioperative chemotherapy (CT) of HER-2 positive gastric (GC) and esophagogastric junction cancer (EGJC): First results of the EORTC 1203 INNOVATION study, in collaboration with the Korean cancer study Group, and the Dutch Upper GI cancer group. J Clin Oncol. 2023;41:4057. https://doi.org/10.1200/JCO.2023.41.16_suppl.4057.

Article  Google Scholar 

Tokunaga M, Machida N, Mizusawa J, Ito S, Yabusaki H, Hirao M, et al. Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan clinical oncology group study JCOG1301C (Trigger Study). Gastric Cancer. 2024;27:580–9. https://doi.org/10.1007/s10120-024-01467-9.

Article  CAS  PubMed  Google Scholar 

Peng Z, Zhang X, Liang H, Zheng Z, Wang Z, Liu H, et al. Atezolizumab and trastuzumab plus chemotherapy in patients with HER2+ locally advanced resectable gastric cancer or adenocarcinoma of the gastroesophageal junction: a multicenter, randomized, open-label phase II study. J Clin Oncol. 2024;42:312. https://doi.org/10.1200/JCO.2024.42.3_suppl.312.

Article  Google Scholar 

Takahari D, Kawazoe A, Machida N, Minashi K, Yamagata Y, Hara H, et al. Phase 2 study of trastuzumab deruxtecan as neoadjuvant treatment for HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003). J Clin Oncol. 2024;42:309. https://doi.org/10.1200/JCO.2024.42.3_suppl.309.

Article  Google Scholar 

Chaganty BKR, Qiu S, Gest A, Lu Y, Ivan C, Calin GA, et al. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion. Cancer Lett. 2018;430:47–56. https://doi.org/10.1016/j.canlet.2018.05.009.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Janjigian YY, Kawazoe A, Yañez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600:727–30. https://doi.org/10.1038/s41586-021-04161-3.